阿托瓦斯塔丁改善了性结肠炎,与肠道微生物群衍生的托芬代谢相关
Yidan Gou1, Shijiao Cai1, Yanyan Chen1
1Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin 300052, China.
阿托瓦斯塔丁可以通过改善肠道微生物群,增强托代谢和修复肠道屏障来缓解性结肠炎 (UC). 这种胆固醇药在小鼠模型中显示出显著的抗炎作用.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 微生物组研究 微生物组研究
背景情况:
- 阿托瓦斯塔丁是一种他类药物,以降低胆固醇而闻名.
- 它的非正规抗炎性质是公认的,但在机制上不清楚.
- 性结肠炎 (UC) 涉及炎症和肠道疾病.
研究的目的:
- 阐明阿托瓦斯塔丁在性结肠炎 (UC) 中的抗炎机制.
- 调查阿托瓦斯塔丁对UC肠道微生物群和托代谢的影响.
- 评估阿托瓦斯塔丁对肠道屏障完整性的影响.
主要方法:
- 在小鼠中使用硫酸 (DSS) 诱导的急性UC.
- 在DSS诱导期间服用阿托瓦斯塔丁.
- 分析了mRNA测序,组织学,炎症标志物,肠道微生物群 (16SrRNA) 和代谢物 (托代谢物).
主要成果:
- 阿托瓦斯塔丁改善了DSS诱导的UC症状,并减少了促炎性细胞因子 (IL-6,TNF-α).
- 正常化肠道微生物群,减少有害细菌,如阿克尔曼西亚和细菌.
- 增加了便中的酸盐及其代谢物 (ILA,IAA),增强了酸碳化合物受体 (AhR) 和IL-22表达.
- 促进了肠道紧结蛋白表达 (ZO-1,ocludin),加强了肠道屏障.
结论:
- 阿托尔瓦斯塔丁通过调节肠道微生物群失生症来有效治疗UC.
- 促进微生物托芬代谢,有助于抗炎作用.
- 修复肠道屏障,为UC提供潜在的治疗策略.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
06:31Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
